Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study

Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Tohru Sonoda, Masaru Iwasaki, Senthilkumar Preethy, View ORCID ProfileSamuel JK Abraham
doi: https://doi.org/10.1101/2021.06.28.21259619
Kadalraja Raghavan
1Department of Paediatric Neurology, Kenmax Medical Service Private Limited, Madurai, India
2Department of Paediatric Neurology, Sarvee Integra Private Limited, Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vidyasagar Devaprasad Dedeepiya
3The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobunao Ikewaki
4Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
5Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tohru Sonoda
5Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Iwasaki
6Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Senthilkumar Preethy
7The Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel JK Abraham
3The Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
6Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
8Antony- Xavier Interdisciplinary Scholastics (AXIS)GN Corporation Co. Ltd., Kofu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel JK Abraham
  • For correspondence: drsam@nichimail.jp drspp@nichimail.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Autism spectrum disorders (ASDs) are a wide range of behavioural disabilities for which there are no definite interventional modalities available. Remedial therapies remain the only option but with varying outcomes. We have evaluated the childhood autism rating scale (CARS) and alpha-synuclein levels in this parallel-group, multiple-arm pilot clinical study after supplementation with a biological response modifier beta-glucan food supplement (Nichi Glucan).

Methods Six subjects with ASD (n = 6) Gr. 1 underwent conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day, and 12 subjects (n = 12) Gr. 2 underwent supplementation with the Nichi Glucan 0.5 g twice daily along with the conventional treatment.

Results There was a significant decrease in the CARS score in all of the children of the Nichi Glucan Gr.2 compared to the control (p-value = 0.034517). Plasma levels of alpha-synuclein were significantly higher in Gr. 2 (Nichi Glucan) than in the control group Gr. 1 (p-value = 0.091701).

Conclusion Improvement of the behavioural pattern CARS score and a correlating alpha-synuclein level, followed by a safe beta-glucan food supplement, warrants further research on other parameters, such as gut-microbiota evaluation, and relevant neuronal biomarkers which is likely to cast light on novel solutions.

Competing Interest Statement

Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the AFO 202 Beta Glucan.

Clinical Trial

CTRI/2020/10/028322

Funding Statement

No external funding was received for the study

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, Madurai, India on 24th August, 2019.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • (drkraghavan27{at}gmail.com)

  • (dedeepiya_76{at}yahoo.co.in)

  • (nikewaki{at}phoenix.ac.jp)

  • (sonoda{at}phoenix.ac.jp)

  • (miwasaki{at}yamanashi.ac.jp)

  • (drspp{at}nichimail.jp)

  • (drsam{at}nichimail.jp)

  • Financial disclosure: No external funding was received for the study

  • Non-financial disclosure: Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the AFO 202 Beta Glucan.

  • Ethical approval: The study was registered in India’s clinical trial registry CTRI, Ref no: CTRI/2020/10/028322. URL: http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=47623&EncHid=&userName=kenmax.

  • The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, Madurai, India on 24th August, 2019.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study
Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Tohru Sonoda, Masaru Iwasaki, Senthilkumar Preethy, Samuel JK Abraham
medRxiv 2021.06.28.21259619; doi: https://doi.org/10.1101/2021.06.28.21259619
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study
Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Tohru Sonoda, Masaru Iwasaki, Senthilkumar Preethy, Samuel JK Abraham
medRxiv 2021.06.28.21259619; doi: https://doi.org/10.1101/2021.06.28.21259619

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (940)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)